Notoginsenoside R1-loaded mesoporous silica nanoparticles targeting the site of injury through inflammatory cells improves heart repair after myocardial infarction

Li, Han; Zhu, Jing; Xu, Yingbin; Mou, Fang-fang; Shan, Xiaoli; Wang, Qiang-Li; Liu, Bao-nian; Ning, Ke; Li, Jiajia; Wang, Ya-Chao; Mi, Jinxia; Wei, Xiaohui; Cui, Guo-Hong; Liu, Rong; Guo, Hai-dong

doi:10.1016/j.redox.2022.102384

Cited by 38 publications

(19 citation statements)

References 67 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A pathway-target network was constructed for the top 18 KEGG pathways that were mainly enriched for the targets (Figure 5A) (Table 3), and the main pathways were found to be enriched for Lipid and atherosclerosis (hsa05417), cAMP signaling pathway (hsa04024), VEGF signaling pathway (hsa04370), inflammatory mediator regulation of TRP channels (hsa04750), exhibiting the multi-target and multi-pathway characteristics of NG-R1 against septic myocardial injury. A large body of literature suggests that septic myocardial injury is associated with inflammation (Glenn and Goldman, 1976;Honda et al, 2019;Xie et al, 2021), and NG-R1 is highly involved in anti-inflammatory regulation (Jiao et al, 2021;Li et al, 2022). Therefore, we hypothesize that the potential mechanism of NG-R1 for sepsis-induced cardiomyopathy may be the regulation of inflammation-related pathways.…”

Section: Go and Kegg Analysismentioning

confidence: 90%

Exploring the molecular mechanism of notoginsenoside R1 in sepsis-induced cardiomyopathy based on network pharmacology and experiments validation

Shao

Li²,

Chen³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Sepsis-induced cardiomyopathy (SIC) is an important manifestation of sepsis, and abnormal cardiac function affects the development of sepsis. Notoginsenoside R1 (NG-R1) is a unique bioactive component of Panax notoginseng with anti-inflammatory and antioxidant effects. However, the effects and possible mechanisms of NG-R1 on SIC are not clear. The purpose of this study was to identify the potential targets and regulatory mechanisms of the action of NG-R1 on SIC. To investigate the potential mechanism, we used network pharmacology, molecular docking, qRT-PCR, and immunofluorescence. The results showed that NG-R1 ameliorated myocardial fibrosis in septic mice. Validation of network pharmacology and molecular docking results revealed that NG-R1 reduced tumor necrosis factor-Alpha (TNF-α) expression in myocardial tissues and AC16 cardiomyocytes in mice, as well as inflammatory factor release in AC16 cells, so TNF-α may be a potential target of NG-R1 against SIC. The present study demonstrated that NG-R1 could protect against SIC and by regulating the expression of TNF-α inflammatory factors, providing a new idea for sepsis drug development.

show abstract

Section: Go and Kegg Analysismentioning

confidence: 90%

Exploring the molecular mechanism of notoginsenoside R1 in sepsis-induced cardiomyopathy based on network pharmacology and experiments validation

Shao

Li²,

Chen³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…All these advantages have led functionalized MSNs to represent a feasible alternative therapy for multiple and diverse diseases that lack effective treatment nowadays. Thus, drug delivery by MSNs has shown promising preclinical results in vivo not only for cancer (including melanoma [116], pancreas [117], bladder [118], breast [119] and osteosarcoma [120], among others), but also myocardium infarction [121], cartilage [122] and bone regeneration [123,124], neurodegenerative diseases, such as ALS [125] or Alzheimer [126] and infection prevention with vaccines [127], to name some.…”

Section: Msns As Drug Delivery Systemsmentioning

confidence: 99%

Key Parameters for the Rational Design, Synthesis, and Functionalization of Biocompatible Mesoporous Silica Nanoparticles

Florensa

Llenas²,

Medina-Gutiérrez³

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Over the last few years, research on silica nanoparticles has rapidly increased. Particularly on mesoporous silica nanoparticles (MSNs), as nanocarriers for the treatment of various diseases because of their physicochemical properties and biocompatibility. The use of MSNs combined with therapeutic agents can provide better encapsulation and effective delivery. MSNs as nanocarriers might also be a promising tool to lower the therapeutic dosage levels and thereby to reduce undesired side effects. Researchers have explored several routes to conjugate both imaging and therapeutic agents onto MSNs, thus expanding their potential as theranostic platforms, in order to allow for the early diagnosis and treatment of diseases. This review introduces a general overview of recent advances in the field of silica nanoparticles. In particular, the review tackles the fundamental aspects of silicate materials, including a historical presentation to new silicates and then focusing on the key parameters that govern the tailored synthesis of functional MSNs. Finally, the biomedical applications of MSNs are briefly revised, along with their biocompatibility, biodistribution and degradation. This review aims to provide the reader with the tools for a rational design of biocompatible MSNs for their application in the biomedical field. Particular attention is paid to the role that the synthesis conditions have on the physicochemical properties of the resulting MSNs, which, in turn, will determine their pharmacological behavior. Several recent examples are highlighted to stress the potential that MSNs hold as drug delivery systems, for biomedical imaging, as vaccine adjuvants and as theragnostic agents.

show abstract

“…This could perhaps suggest that NP-based stem cell therapy will translate to clinical practice in the near future. Moreover, several Chinese herbal medicines (TCM) have been shown to improve cardiac function after MI [24,25]. NP-based delivery system can be a novel option for researchers to study TCM and perhaps have positive clinical effects in the management of MI and CVDs in the future.…”

Section: Challenges and Opportunitiesmentioning

confidence: 99%

Nanoparticle-based Drug Delivery System for Post Myocardial Infarction Management

Liu¹,

Ramponi²,

Fan³

et al. 2022

IJDDP

View full text Add to dashboard Cite

Review Nanoparticle-based Drug Delivery System for Post Myocardial Infarction Management Minxuan Liu, Chiara Ramponi, Xiaoxue Fan, Xinzhuang Zhang, Liang Cao, Zhenzhong Wang, and Wei Xiao * State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang, 222001, China. * Correspondence: xw_kanion@163.com Received: 15 October 2022 Accepted: 2 November 2022 Published: 21 December 2022 Abstract: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the world. Myocardial infraction (MI) as one of the most harmful forms of ischaemic heart disease requires rigorous and tempestive approaches which are not met by current clinical interventions. Nanotechnology has developed promising clinical applications for imaging, diagnostic, gene delivery and tissue engineering, which makes this technology a potential candidate for novel therapeutic delivery approach. This review highlights several recent research reports regarding advances in drug delivery using nanoparticle-based (NP) strategies, as well as future challenges and opportunities.

show abstract

Notoginsenoside R1-loaded mesoporous silica nanoparticles targeting the site of injury through inflammatory cells improves heart repair after myocardial infarction

Cited by 38 publications

References 67 publications

Exploring the molecular mechanism of notoginsenoside R1 in sepsis-induced cardiomyopathy based on network pharmacology and experiments validation

Exploring the molecular mechanism of notoginsenoside R1 in sepsis-induced cardiomyopathy based on network pharmacology and experiments validation

Key Parameters for the Rational Design, Synthesis, and Functionalization of Biocompatible Mesoporous Silica Nanoparticles

Nanoparticle-based Drug Delivery System for Post Myocardial Infarction Management

Contact Info

Product

Resources

About